RTC-5 (Synonyms: TRC-382) |
| Catalog No.GC37568 |
RTC-5 (TRC-382) est une phénothiazine optimisée au pouvoir anticancéreux. RTC-5 démontre une efficacité contre un modèle de xénogreffe d'un cancer induit par l'EGFR, ses effets sont attribués À une régulation négative concomitante de la signalisation PI3K-AKT et RAS-ERK.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1423077-49-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
RTC-5 is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling[1]. IC50: EGFR[1]
RTC-5 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 12.6μM[1].RTC-5 (20-40 μM; 24 hours) negatively regulates PI3K-AKT and RAS-ERK pathways by decreasing phospho-AKT and phospho-ERK levels expression[1]. Cell Viability Assay[1] Cell Line: H1650 lung adenocarcinoma cells
[1]. Kastrinsky DB, et al. Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *